NewLimit
PrivateLast Round
Series B
May 6, 2025
Est. Valuation
$810M
Total Funding Raised
$170M
Momentum Score
50 /100
Company Overview
NewLimit is a biotechnology company specializing in anti-aging technology that aims to reverse the aging process and enhance human life expectancy through epigenetic reprogramming therapies and single-cell sequencing to rejuvenate tissue across the body.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewLimit Comps
Public and private peers based on sector, stage, and business model.
NewLimit Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 6, 2025 | ||||
| Series A | May 16, 2023 |
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
BID | |||||
BID |
NewLimit Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series B |
| Khosla Ventures | Series B |
| Founders Fund | Series B, Series A |
| Valor Equity Partners | Series B |
| Dimension | Series B |
| Dimension | Series B |
| Kleiner Perkins | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Active program targets vascular endothelial integrity in aged and diseased patients.
- Jan 1, 2026
Active program to restore T cell immunity in aged and diseased patients.
NewLimit Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NewLimit's valuation, stock price, and market status.
